{"entity":{"id":"rondecabtagene-autoleucel","kind":"drug","name":"Rondecabtagene autoleucel","aka":[],"tldr":"Rondecabtagene autoleucel is an experimental CAR-T cell therapy from Lyell Immunopharma in phase 3 trials for diffuse large B-cell lymphoma and hodgkin lymphoma, aimed at CD19 and CD20.","summary":"Rondecabtagene autoleucel (LYL314) is a CAR-T cell therapy developed by Lyell Immunopharma. Its targets are CD19 and CD20 (the sponsor names CD19/CD20). The sponsor states: An autologous, dual-targeting CD19/CD20 CAR T-cell product using an OR-gated CAR construct that fully activates on recognition of either antigen, enriched for CD62L-positive naive/central memory T cells for enhanced proliferation and persistence. ClinicalTrials.gov describes the intervention as: An autologous, dual-targeting CD19/20 CAR T-cell candidate. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07188558 (A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy), in diffuse large B-cell lymphoma and hodgkin lymphoma. The largest, NCT07188558, plans to enrol 400 participants with primary completion expected 2029-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Rondecabtagene autoleucel","url":"https://clinicaltrials.gov/search?intr=LYL314"},{"label":"Sponsor pipeline page","url":"http://www.lyell.com/pipeline"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["dlbcl","hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":["cd19","cd20"],"drugs":[],"companies":["lyell-immunopharma"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07188558","nct05826535"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"LYL314","modality":"CAR-T cell therapy","mechanism":"An autologous, dual-targeting CD19/CD20 CAR T-cell product using an OR-gated CAR construct that fully activates on recognition of either antigen, enriched for CD62L-positive naive/central memory T cells for enhanced proliferation and persistence.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/rondecabtagene-autoleucel/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"},{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"}],"company":[{"id":"lyell-immunopharma","kind":"company","name":"Lyell Immunopharma","route":"/companies/lyell-immunopharma/"}],"trial":[{"id":"nct07188558","kind":"trial","name":"A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy","route":"/trials/nct07188558/"},{"id":"nct05826535","kind":"trial","name":"Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma","route":"/trials/nct05826535/"}]}}